Repligen Appoints Olivier Loeillot As Chief Executive Officer, Effective September 1, 2024

6/13/24 7:07:18 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $RGEN alert in real time by email

Board of Directors approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of Lead Independent Director.

Get the next $RGEN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RGEN

Date	Price Target	Rating	Analyst
11/14/2024		Peer Perform	Wolfe Research
8/28/2024	$180.00	Overweight	Wells Fargo
6/26/2024	$180.00 → $155.00	Hold → Buy	Deutsche Bank
6/18/2024		Neutral	Guggenheim
12/4/2023		Buy → Hold	The Benchmark Company
7/20/2023	$185.00	Overweight	Wells Fargo
7/5/2023	$220.00	Overweight	JP Morgan
3/28/2023	$230.00	Buy	The Benchmark Company

More analyst ratings

Repligen Announces CEO Transition Plan
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of
6/13/24 7:00:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen's board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business
3/19/24 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer
WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has appointed 20+ year industry veteran Olivier Loeillot to the newly created position of President and Chief Commercial Officer (CCO), effective immediately. Mr. Loeillot served a combined 12 years with Cytiva (a Danaher company) and GE Healthcare Life Sciences. In his most recent role at Cytiva, he served as Bioprocess President from 2018 to 2022, overseeing the overall Bioprocess portfolio from cell culture media to purification resins and including process equipment, single-use technologies and enterprise s
10/2/23 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Repligen Reports Third Quarter 2024 Financial Results
Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today's webcast a
11/12/24 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Repligen Corporation to Present at Upcoming Investor Conferences
WALTHAM, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at three upcoming investor conferences. The UBS Global Healthcare Conference being held November 11-14 in Rancho Palos Verdes, CA. Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Thursday, November 14, at 10:15 a.m. ET.The Stifel Healthcare Conference being held November 18-19 in New York City. Olivier Loeillot, Chief Executive Officer, and Jason Garland, Chief Financial Officer, will participate in an analyst-led discussion on Tuesday, November 19,
11/5/24 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Repligen to Report Third Quarter 2024 Financial Results
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeillot, President and Chief Executive Officer of Repligen said, "Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required
10/31/24 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$RGEN
Financials

Live finance-specific insights

Repligen Reports Third Quarter 2024 Financial Results
Third quarter reported revenue of $155 million, an increase of 10% year-over-yearCDMO revenue and orders both up ~20% year-over-yearOverall order intake outpaced sales by 4% Full year revenue guidance narrowed to range of $630-$639 million WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its third quarter (Q3) of 2024, covering the three- and nine- month periods ended September 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and access information for today's webcast a
11/12/24 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Repligen to Report Third Quarter 2024 Financial Results
WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2024 financial results on Tuesday, November 12, 2024. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and nine- month reporting periods ended September 30, 2024. Olivier Loeillot, President and Chief Executive Officer of Repligen said, "Our team continues to work diligently to complete the required revenue restatements as disclosed on September 18. We plan to file the amended periodic reports related to the required
10/31/24 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Repligen Reports Second Quarter 2024 Financial Results
Reports second quarter revenue of $154 millionSecond quarter orders of $157 millionBook-to-bill 1.02 for the quarter, 1.01 year-to-dateAchieved first half revenue and order targetsNarrows revenue guidance within previous range for fiscal year 2024; adjusted EPS guidance unchanged WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter (Q2) of 2024, covering the three- and six- month periods ended June 30, 2024. Provided in this press release are financial performance highlights, updates to our guidance for the full year 2024 and acce
7/30/24 7:30:00 AM ET
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Repligen Appoints Olivier Loeillot As Chief Executive Officer, Effective September 1, 2024

Chat with this insight

Recent Analyst Ratings for $RGEN

$RGEN Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Wolfe Research initiated coverage on Repligen

Wells Fargo initiated coverage on Repligen with a new price target

Repligen upgraded by Deutsche Bank with a new price target

$RGEN Market Insights

Live Market Insights

Repligen Discovers Unauthorized Access To Information Systems; Engages Cybersecurity Experts And Notifies Law Enforcement; Incident Has Not Impacted Business Operations Or Financial Condition; Investigation Ongoing To Determine Full Impact And Necessary Notifications

Repligen shares are trading higher after Deutsche Bank upgraded the stock from Hold to Buy but cut its price target from $180 to $155.

This Robinhood Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

$RGEN Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)

Director Barthelemy Nicolas bought $150,540 worth of shares (1,200 units at $125.45), increasing direct ownership by 35% to 4,668 units (SEC Form 4)

Chief Executive Officer Hunt Anthony bought $248,160 worth of shares (2,000 units at $124.08), increasing direct ownership by 1% to 165,177 units (SEC Form 4)

$RGEN Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

CFO Garland Jason K covered exercise/tax liability with 367 shares, decreasing direct ownership by 5% to 7,676 units (SEC Form 4)

Chief Executive Officer Loeillot Olivier covered exercise/tax liability with 861 shares, decreasing direct ownership by 3% to 32,556 units (SEC Form 4)

Director Muir Glenn P exercised 19,000 shares at a strike of $36.29, increasing direct ownership by 143% to 32,283 units (SEC Form 4)

$RGEN Leadership Updates

Live Leadership Updates

$RGEN SEC Filings

$RGEN Large Ownership Changes

This live feed shows all institutional transactions in real time.

$RGEN Press Releases

Fastest customizable press release news feed in the world

Repligen Announces CEO Transition Plan

Repligen Appoints Maggie A. Pax to Board of Directors

Repligen Appoints Olivier Loeillot as President and Chief Commercial Officer

SEC Form 10-Q filed by Repligen Corporation

Amendment: SEC Form 10-Q/A filed by Repligen Corporation

Amendment: SEC Form 10-Q/A filed by Repligen Corporation

Amendment: SEC Form SC 13G/A filed by Repligen Corporation

Amendment: SEC Form SC 13G/A filed by Repligen Corporation

SEC Form SC 13G/A filed by Repligen Corporation (Amendment)

Repligen Reports Third Quarter 2024 Financial Results

Repligen Corporation to Present at Upcoming Investor Conferences

Repligen to Report Third Quarter 2024 Financial Results

$RGEN Financials

Live finance-specific insights

Repligen Reports Third Quarter 2024 Financial Results

Repligen to Report Third Quarter 2024 Financial Results

Repligen Reports Second Quarter 2024 Financial Results

Recent Analyst Ratings for
$RGEN

$RGEN
Analyst Ratings

$RGEN
Market Insights

$RGEN
Insider Purchases

$RGEN
Insider Trading

$RGEN
Leadership Updates

$RGEN
SEC Filings

$RGEN
Large Ownership Changes

$RGEN
Press Releases

$RGEN
Financials